University of Illinois Chicago
Browse

Nanotechnology in Corneal Neovascularization Therapy—A Review

Download (271.39 kB)
journal contribution
posted on 2014-01-02, 00:00 authored by Lilian Gonzalez, Raymond J. Loza, Kyu-Yeon Han, Suhair Sunoqrot, Christy Cunningham, Patryk Purta, James Drake, Sandeep Jain, Seungpyo Hong, Jin-Hong Chang
Nanotechnology is an up-and-coming branch of science that studies and designs materials with at least one dimension sized from 1-100 nm. These nanomaterials have unique functions at the cellular, atomic, and molecular levels. 1 The term "nanotechnology" was first coined in 1974.(2) Since then, it has evolved dramatically and now consists of distinct and independent scientific fields. Nanotechnology is a highly studied topic of interest, as nanoparticles can be applied to various fields ranging from medicine and pharmacology, to chemistry and agriculture, to environmental science and consumer goods. 3 The rapidly evolving field of nanomedicine incorporates nanotechnology with medical applications, seeking to give rise to new diagnostic means, treatments, and tools. Over the past two decades, numerous studies that underscore the successful fusion of nanotechnology with novel medical applications have emerged. This has given rise to promising new therapies for a variety of diseases, especially cancer. It is becoming abundantly clear that nanotechnology has found a place in the medical field by providing new and more efficient ways to deliver treatment. Ophthalmology can also stand to benefit significantly from the advances in nanotechnology research. As it relates to the eye, research in the nanomedicine field has been particularly focused on developing various treatments to prevent and/or reduce corneal neovascularization among other ophthalmologic disorders. This review article aims to provide an overview of corneal neovascularization, currently available treatments, and where nanotechnology comes into play.

Funding

This work was partially supported by National Institutes of Health grants UL1TR000050 and EY001792 and EY021886 (JHC) and an unrestricted grant from Research to Prevent Blindness, New York, NY.

History

Publisher Statement

This is a copy of an article published in the Journal of Ocular Pharmacology and Therapeutics © 2013 Copyright Mary Ann Liebert, Inc.; Journal of Ocular Pharmacology and Therapeutics is available online at: http://www.liebertonline.com.

Publisher

Mary Ann Liebert

Language

  • en_US

issn

1080-7683

Issue date

2013-03-01

Usage metrics

    Categories

    No categories selected

    Keywords

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC